Section Arrow
XERS.NASDAQ
- Xeris Biopharma Holdings
Quotes are at least 15-min delayed:2024/05/16 10:54 EDT
Last
 2.0573
+0.0773 (+3.90%)
Day High 
2.07 
Prev. Close
1.98 
1-M High
2.05 
Volume 
636.92K 
Bid
2.05
Ask
2.06
Day Low
1.93 
Open
1.98 
1-M Low
1.69 
Market Cap 
293.55M 
Currency USD 
P/E -- 
%Yield
10-SMA 1.88 
20-SMA 1.82 
50-SMA 1.99 
52-W High 3.26 
52-W Low 1.46 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.47/-0.08
Enterprise Value
519.24M
Balance Sheet
Book Value Per Share
-0.06
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
163.91M
Operating Revenue Per Share
0.90
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.0948+0.0171+22.01%-- 
JAGXJaguar Health0.2675+0.0124+4.86%-- 
DNAGinkgo Bioworks Holdings0.818-0.0211-2.51%-- 
NVAXNovavax12.8928-0.0072-0.06%-- 
NBYNovaBay Pharmaceuticals0.1045--0.000%-- 
Quotes are at least 15-min delayed:2024/05/16 10:54 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.